Several drugs were identified and ranked based on their potential to disrupt this signaling network; notably alisertib, a highly specific inhibitor of AURKA, which has been previously reported for its beneficial effect in combination with BRAF and MEK inhibitors in melanoma treatment (40, 49). Here, BRAF is linked to melanoma.